BackFreeline Therapeutics Holdings plc Overview

Freeline Therapeutics Holdings plc Current Assets

Track Freeline Therapeutics Holdings plc's current assets ($34M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$34.00M
54.12% YoYΔ $-40.11M vs prior year quarter

Peer trimmed avg / median

Loading

Freeline Therapeutics Holdings plc Current Assets History

Loading

Freeline Therapeutics Holdings plc vs. peers: Current Assets Comparison

Loading

Freeline Therapeutics Holdings plc Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Freeline Therapeutics Holdings plc (FRLN) FAQ

Freeline Therapeutics Holdings plc's current assets stands at $34M as of September 2023. That compares with $74M in the prior-year period — down 54.1% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Freeline Therapeutics Holdings plc reported $34M in current assets versus $74M a year earlier — a 54.1% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $74M in the prior-year period — down 54.1% year over year. Sustained growth in current assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Freeline Therapeutics Holdings plc's current assets evolved across reporting periods, while the comparison chart places FRLN next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, current assets is commonly used to spot outliers. Freeline Therapeutics Holdings plc's reading of $34M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.